Key positives include a clean, debt‑free balance sheet with solid near‑term liquidity; a clear scientific focus on fibro‑inflammatory diseases; a potentially first‑in‑class therapy with novel mechanism and encouraging mid‑stage data; and strong regulatory and intellectual property positioning. Operating costs outside of R&D appear disciplined, with spending concentrated where it most directly supports the clinical pipeline.

Major risks stem from the lack of any revenue, persistent and material losses, and ongoing cash burn, which together create dependence on external financing and potential shareholder dilution. Clinical and regulatory uncertainty around late‑stage trials is high, and the company’s fortunes are heavily tied to a single lead asset and a narrow disease focus. Competition from larger or more diversified players in rare liver and fibrotic diseases, as well as possible delays or setbacks in trials or partnering, add to the overall risk profile.

Looking ahead, Chemomab’s trajectory will largely be determined by execution of its planned Phase 3 trial in PSC, the ability to expand nebokitug into additional indications, and success in securing strategic or financing partnerships to fund these efforts. Outcomes are likely to be binary‑like, with significant potential value creation if clinical and regulatory milestones are met, and considerable downside if key trials disappoint or capital access tightens. Overall, the company’s future rests on converting its scientific edge into clinical proof and sustainable commercial economics.